Prognostic value of epigenomic profiling in lung cancer
Author(s) -
Alok Mishra,
Mukesh Verma
Publication year - 2019
Publication title -
translational cancer research
Language(s) - English
DOI - 10.21037/28188
Among all types of lung cancers, non-small cell lung cancer (NSCLC) is the most common cause of cancer-associated death. Conventional therapy of NSCLC includes radiation, surgery, and cis-platin therapy. However, other approaches of treatment, including epigenetic therapy, have been proposed (1-4).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom